These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 39023497)

  • 21. Diffusion Tensor Cardiovascular Magnetic Resonance in Cardiac Amyloidosis.
    Khalique Z; Ferreira PF; Scott AD; Nielles-Vallespin S; Martinez-Naharro A; Fontana M; Hawkins P; Firmin DN; Pennell DJ
    Circ Cardiovasc Imaging; 2020 May; 13(5):e009901. PubMed ID: 32408830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiac Magnetic Resonance T
    Duca F; Kammerlander AA; Panzenböck A; Binder C; Aschauer S; Loewe C; Agis H; Kain R; Hengstenberg C; Bonderman D; Mascherbauer J
    JACC Cardiovasc Imaging; 2018 Dec; 11(12):1924-1926. PubMed ID: 30121265
    [No Abstract]   [Full Text] [Related]  

  • 23. PET-CT evaluation of amyloid systemic involvement with [
    Genovesi D; Vergaro G; Emdin M; Giorgetti A; Marzullo P
    J Nucl Cardiol; 2017 Dec; 24(6):2025-2029. PubMed ID: 28326465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abnormal pulmonary
    Pittman S; Sethi P; Flavell RR; De Marco T; Hernandez Pampaloni M
    J Nucl Cardiol; 2018 Oct; 25(5):1865-1868. PubMed ID: 29101671
    [No Abstract]   [Full Text] [Related]  

  • 25. Cardiac Amyloidosis Detected Using
    García-González P; Cozar-Santiago MDP; Maceira AM
    Rev Esp Cardiol (Engl Ed); 2016 Dec; 69(12):1215. PubMed ID: 27178118
    [No Abstract]   [Full Text] [Related]  

  • 26. Non-invasive detection and differentiation of cardiac amyloidosis using
    Takasone K; Katoh N; Takahashi Y; Abe R; Ezawa N; Yoshinaga T; Yanagisawa S; Yazaki M; Oguchi K; Koyama J; Sekijima Y
    Amyloid; 2020 Dec; 27(4):266-274. PubMed ID: 32722948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A consecutive case series experience with [18 F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition.
    Mitsis EM; Bender HA; Kostakoglu L; Machac J; Martin J; Woehr JL; Sewell MC; Aloysi A; Goldstein MA; Li C; Sano M; Gandy S
    Mol Neurodegener; 2014 Feb; 9():10. PubMed ID: 24484858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 18F-Florbetapir PET in Primary Cerebral Amyloidoma.
    Soffers F; Ceyssens S; Buffet W; de Surgeloose D; Crols R
    Clin Nucl Med; 2020 Oct; 45(10):838-839. PubMed ID: 32796236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Semiautomated Method for Quantification of F 18 Florbetapir PET Images.
    Joshi AD; Pontecorvo MJ; Lu M; Skovronsky DM; Mintun MA; Devous MD
    J Nucl Med; 2015 Nov; 56(11):1736-41. PubMed ID: 26338898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reproducibility and Repeatability of Assessment of Myocardial Light Chain Amyloidosis Burden Using
    Nodoushani A; El-Sady MS; Park MA; Castilloveitia GL; Falk RH; Di Carli MF; Kijewski MF; Dorbala S
    J Nucl Cardiol; 2021 Oct; 28(5):2004-2010. PubMed ID: 31758410
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Schindler TH; Sharma V; Imperiale A
    JACC Cardiovasc Imaging; 2021 Jan; 14(1):256-258. PubMed ID: 32771579
    [No Abstract]   [Full Text] [Related]  

  • 32. Myocardial Amyloidosis: The Exemplar Interstitial Disease.
    Fontana M; Ćorović A; Scully P; Moon JC
    JACC Cardiovasc Imaging; 2019 Nov; 12(11 Pt 2):2345-2356. PubMed ID: 31422120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Examining the sensitivity of 18F-NaF PET for the imaging of cardiac amyloidosis.
    Martineau P; Finnerty V; Giraldeau G; Authier S; Harel F; Pelletier-Galarneau M
    J Nucl Cardiol; 2021 Feb; 28(1):209-218. PubMed ID: 30834499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early Phase
    Galat A; Van der Gucht A; Guellich A; Bodez D; Cottereau AS; Guendouz S; Hittinger L; Dubois-Randé JL; Plante-Bordeneuve V; Itti E; Meignan M; Damy T; Rosso J
    JACC Cardiovasc Imaging; 2017 May; 10(5):601-603. PubMed ID: 27424245
    [No Abstract]   [Full Text] [Related]  

  • 35. Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis.
    Ridouani F; Damy T; Tacher V; Derbel H; Legou F; Sifaoui I; Audureau E; Bodez D; Rahmouni A; Deux JF
    J Cardiovasc Magn Reson; 2018 Aug; 20(1):58. PubMed ID: 30115079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Performance of
    Awaya T; Minamimoto R; Iwama K; Kubota S; Hotta M; Hirai R; Yamamoto M; Okazaki O; Hara H; Hiroi Y; Hiroe M; Moroi M
    J Nucl Cardiol; 2020 Aug; 27(4):1145-1153. PubMed ID: 31591695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation between brain glucose metabolism (
    Albano D; Premi E; Peli A; Camoni L; Bertagna F; Turrone R; Borroni B; Calhoun VD; Rodella C; Magoni M; Padovani A; Giubbini R; Paghera B
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(3):146-152. PubMed ID: 35577490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [18F]-Florbetaben PET/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, and Mimicking Conditions.
    Genovesi D; Vergaro G; Giorgetti A; Marzullo P; Scipioni M; Santarelli MF; Pucci A; Buda G; Volpi E; Emdin M
    JACC Cardiovasc Imaging; 2021 Jan; 14(1):246-255. PubMed ID: 32771577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is 18F-flutemetamol PET/CT able to reveal cardiac amyloidosis?
    Lhommel R; Sempoux C; Ivanoiu A; Michaux L; Gerber B
    Clin Nucl Med; 2014 Aug; 39(8):747-9. PubMed ID: 24978329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Misconceptions and Facts About Cardiac Amyloidosis.
    Nguyen FD; Rodriguez M; Krittanawong C; Witteles R; Lenihan DJ
    Am J Cardiol; 2021 Dec; 160():99-105. PubMed ID: 34610875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.